We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ESC 2024 - Jessica Schubert shares the results of a Swedish nationwide cohort study among patients with MI. Achieving the non-HDL-c target early after MI, and sustaining it over the first year after MI was associated with the lowest risk of CV outcomes.
This video was recorded during the ESC Congress 2024 in London, UK.
Jessica Schubert, MD is a specialist in clinical pharmacology at Uppsala University Hospital in Sweden. She is a PhD student at the department of Medical Sciences of Uppsala University.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 1 September 2024
ESC 2024 - Jessica Schubert shares the results of a Swedish nationwide cohort study among patients with MI. Achieving the non-HDL-c target early after MI, and sustaining it over the first year after MI was associated with the lowest risk of CV outcomes.
This video was recorded during the ESC Congress 2024 in London, UK.
Jessica Schubert, MD is a specialist in clinical pharmacology at Uppsala University Hospital in Sweden. She is a PhD student at the department of Medical Sciences of Uppsala University.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 1 September 2024
Stay current with the best on medical education
